Fludarabine (Conditional therapy)

DRUG2 trials

Sponsors

CARGO Therapeutics, University of Kansas Medical Center

Conditions

B-Cell Non-Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaCancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)

Phase 1

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

RecruitingNCT06879340

University of Kansas Medical CenterB-cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma

Start: 2025-03-31End: 2040-03-01Target: 54Updated: 2026-05-14

Phase 2

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

TerminatedNCT05972720

CARGO TherapeuticsCancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Start: 2023-08-01End: 2025-04-04Updated: 2025-05-15

Related Papers

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood2025-11-03

Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.

Journal of Clinical Oncology2024-06-011 citations